• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [6756 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2018 Agency for Healthcare Research and Quality (AHRQ) Drug therapy for early rheumatoid arthritis: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Effectiveness of indoor allergen reduction in management of asthma
2018 Agency for Healthcare Research and Quality (AHRQ) Intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma
2018 Agency for Healthcare Research and Quality (AHRQ) Lower limb prostheses: measurement instruments, comparison of component effects by subgroups, and long-term outcomes
2018 Agency for Healthcare Research and Quality (AHRQ) Mobile applications for self-management of diabetes
2018 Agency for Healthcare Research and Quality (AHRQ) Noninvasive nonpharmacological treatment for chronic pain: a systematic review
2018 Agency for Healthcare Research and Quality (AHRQ) Nonsurgical treatments for urinary incontinence in women: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Patient navigation models for lung cancer
2018 Agency for Healthcare Research and Quality (AHRQ) Physiologic predictors of severe injury: systematic review
2018 Agency for Healthcare Research and Quality (AHRQ) Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Role of immunotherapy in the treatment of asthma
2018 Agency for Healthcare Research and Quality (AHRQ) Sodium and potassium intake: effects on chronic disease outcomes and risks
2018 Agency for Healthcare Research and Quality (AHRQ) Stroke prevention in patients with atrial fibrillation: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Treatment for bipolar disorder in adults: a systematic review
2018 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of ambulatory electrocardiography technologies for the diagnosis of cardiac arrhythmia]
2018 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the ultrasonic flowmeter for verification of graft patency during coronary artery bypass grafting]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Femoral neck fracture: evaluation of the hospital care process]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of bariatric surgery in individuals with morbid obesity]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Analysis of diagnostic performance of transbronchial lung biopsy using cryoprobe (cryobiopsy) in the study of diffuse lung diseases]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment. Update]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Shoulder arthroscopy: appropriate use]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Effectiveness and cost-effectiveness of bilateral cochlear implants in children and adults]
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Effects of lung volume reduction with endobronchial valves in patients with severe chronic obstructive pulmonary disease. Updated report
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Gender affirmation surgery for gender dysphoria - effects and risks
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Effects of passive movement therapy in patients with stroke, spinal cord injury, or need of intensive care
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy of the Swedish model for physical activity on prescription
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Triage for prioritisation in the emergency department
2018 National Institute for Health and Care Excellence (NICE) Golimumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 497
2018 National Institute for Health and Care Excellence (NICE) Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 498
2018 National Institute for Health and Care Excellence (NICE) Glecaprevir–pibrentasvir for treating chronic hepatitis C. NICE technology appraisal guidance 499
2018 National Institute for Health and Care Excellence (NICE) Ceritinib for untreated ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 500
2018 National Institute for Health and Care Excellence (NICE) Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. NICE technology appraisal guidance 501
2018 National Institute for Health and Care Excellence (NICE) Ibrutinib for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 502
2018 National Institute for Health and Care Excellence (NICE) Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer. NICE technology appraisal guidance 503
2018 National Institute for Health and Care Excellence (NICE) Pirfenidone for treating idiopathic pulmonary fibrosis. NICE technology appraisal guidance 504
2018 National Institute for Health and Care Excellence (NICE) Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C. NICE technology appraisal guidance 507
2018 National Institute for Health and Care Excellence (NICE) Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee. NICE technology appraisal guidance 508
2018 National Institute for Health and Care Excellence (NICE) Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer. NICE technology appraisal guidance 509
2018 National Institute for Health and Care Excellence (NICE) Brodalumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 511
2018 National Institute for Health and Care Excellence (NICE) Tivozanib for treating advanced renal cell carcinoma. NICE technology appraisal guidance 512
2018 National Institute for Health and Care Excellence (NICE) Obinutuzumab for untreated advanced follicular lymphoma. NICE technology appraisal guidance 513
2018 National Institute for Health and Care Excellence (NICE) Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen. NICE technology appraisal guidance 515
2018 National Institute for Health and Care Excellence (NICE) Cabozantinib for treating medullary thyroid cancer. NICE technology appraisal guidance 516
2018 National Institute for Health and Care Excellence (NICE) Avelumab for treating metastatic Merkel cell carcinoma. NICE technology appraisal guidance 517
2018 National Institute for Health and Care Excellence (NICE) Tocilizumab for treating giant cell arteritis. NICE technology appraisal guidance 518
2018 National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 520
2018 National Institute for Health and Care Excellence (NICE) Guselkumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 521
2018 National Institute for Health and Care Excellence (NICE) Midostaurin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 523
2018 National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 524
2018 National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 525
2018 National Institute for Health and Care Excellence (NICE) Arsenic trioxide for treating acute promyelocytic leukaemia. NICE technology appraisal guidance 526
2018 National Institute for Health and Care Excellence (NICE) Beta interferons and glatiramer acetate for treating multiple sclerosis. NICE technology appraisal guidance 527
2018 National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 529
2018 National Institute for Health and Care Excellence (NICE) Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. NICE technology appraisal guidance 530
2018 National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2018 National Institute for Health and Care Excellence (NICE) Ocrelizumab for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 533
2018 National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 534
2018 National Institute for Health and Care Excellence (NICE) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. NICE technology appraisal guidance 535
2018 National Institute for Health and Care Excellence (NICE) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 536
2018 National Institute for Health and Care Excellence (NICE) Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 537
2018 National Institute for Health and Care Excellence (NICE) Dinutuximab beta for treating neuroblastoma. NICE technology appraisal guidance 538
2018 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 540
2018 National Institute for Health and Care Excellence (NICE) Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. NICE technology appraisal guidance 541
2018 National Institute for Health and Care Excellence (NICE) Cabozantinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 542
2018 National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 543
2018 National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 544
2018 National Institute for Health and Care Excellence (NICE) Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 545
2018 National Institute for Health and Care Excellence (NICE) Padeliporfin for untreated localised prostate cancer. NICE technology appraisal guidance 546
2018 National Institute for Health and Care Excellence (NICE) Tofacitinib for moderately to severely active ulcerative colitis. NICE technology appraisal guidance 547
2018 National Institute for Health and Care Excellence (NICE) Decitabine for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 548
2018 National Institute for Health and Care Excellence (NICE) Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal). NICE technology appraisal guidance 549
2018 National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2018 National Institute for Health and Care Excellence (NICE) Lenvatinib for untreated advanced hepatocellular carcinoma. NICE technology appraisal guidance 551
2018 National Institute for Health and Care Excellence (NICE) Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 552
2018 National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2018 National Institute for Health and Care Excellence (NICE) Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. NICE interventional procedures guidance 634
2018 National Institute for Health and Care Excellence (NICE) Bronchial thermoplasty for severe asthma. NICE interventional procedures guidance 635
2018 National Institute for Health and Care Excellence (NICE) Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain. NICE interventional procedures guidance 632
2018 National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions. NICE interventional procedures guidance 633
2018 National Institute for Health and Care Excellence (NICE) Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis. NICE interventional procedures guidance 631
2018 National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma. NICE interventional procedures guidance 630
2018 National Institute for Health and Care Excellence (NICE) Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. NICE interventional procedures guidance 628
2018 National Institute for Health and Care Excellence (NICE) Leadless cardiac pacemaker implantation for bradyarrhythmias. NICE interventional procedures guidance 626
2018 National Institute for Health and Care Excellence (NICE) Superior rectal artery embolisation for haemorrhoids. NICE interventional procedures guidance 627
2018 National Institute for Health and Care Excellence (NICE) Sutureless aortic valve replacement for aortic stenosis. NICE interventional procedures guidance 624
2018 National Institute for Health and Care Excellence (NICE) Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 625
2018 National Institute for Health and Care Excellence (NICE) Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing. NICE interventional procedures guidance 621
2018 National Institute for Health and Care Excellence (NICE) Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing. NICE interventional procedures guidance 622
2018 National Institute for Health and Care Excellence (NICE) Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures. NICE interventional procedures guidance 623
2018 National Institute for Health and Care Excellence (NICE) Superior capsular augmentation for massive rotator cuff tears. NICE interventional procedures guidance 619
2018 National Institute for Health and Care Excellence (NICE) Transaxial interbody lumbosacral fusion for severe chronic low back pain. NICE interventional procedures guidance 620
2018 National Institute for Health and Care Excellence (NICE) Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor. NICE interventional procedures guidance 617
2018 National Institute for Health and Care Excellence (NICE) Laparoscopic ventral mesh rectopexy for internal rectal prolapse. NICE interventional procedures guidance 618
2018 National Institute for Health and Care Excellence (NICE) Intranasal phototherapy for allergic rhinitis. NICE interventional procedures guidance 616
2018 National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer. NICE interventional procedures guidance 614
2018 National Institute for Health and Care Excellence (NICE) Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. NICE interventional procedures guidance 615
2018 National Institute for Health and Care Excellence (NICE) Percutaneous balloon valvuloplasty for fetal critical aortic stenosis. NICE interventional procedures guidance 613
2018 National Institute for Health and Care Excellence (NICE) Robot-assisted kidney transplant. NICE interventional procedures guidance 609